Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1140022110057 | Other Grant/Funding Number | ZonMw |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ZonMw: The Netherlands Organisation for Health Research and Development | OTHER |
Not provided
Not provided
Not provided
Phase 2 clinical trial on the addition of dutasteride to combined androgen blockade (CAB) therapy in recurrent and/or metastatic (R/M) salivary duct carcinoma (SDC) patients.
The study included two cohorts of patients: Cohort A, which comprises ADT-naïve patients, and Cohort B, which comprises ADT-resistant patients.
Cohort A is closed for inclusion as of April 18, 2024.
A prospective, randomized controlled, single-institution, phase II clinical trial to assess the objective response rate (ORR), duration of response (DoR), progression free survival (PFS), overall survival (OS), toxicity, quality of life (QoL), and expression of molecular targets of patients with R/M SDC treated with either combined androgen blockade (CAB; goserelin + bicalutamide) or CAB + dutasteride, Participants in Cohort A will be randomized 1:1 at the study entry to receive CAB (goserelin 10.8 mg/3months + bicalutamide 50 mg/once daily) or CAB + dutasteride (0.5 mg/once daily). Participants will receive treatment until until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Cohort A is closed for inclusion as of April 18, 2024.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Combined androgen blockade (CAB) + dutasteride | Experimental | Patients from cohort B (ADT-resistant) will receive CAB+dutasteride. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Goserelin 10.8 mg | Drug | Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate (ORR) | Response will be measured according to RECIST version 1.1, the ORR is defined as the sum of the complete remissions plus partial responses. The best response will be used in each patient. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Duration of Response (DoR) | Response will be measured according to RECIST version 1.1, the DoR is defined as the time from first tumor assessment at which the overall response was recorded as partial response (PR) or complete response (CR) that is subsequently confirmed until documented progressive disease (PD) or death form any cause, whichever occurs first. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival (PFS) | Response will be measured according to RECIST version 1.1, the PFS is defined as the time from study enrolment until date of first documented disease progression or death due to any cause, whichever occurs first.Every 12 weeks a CT/MRI scan will be made to asses the progression free survival until PD. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| C.M.L. Van Herpen, Prof. MD. PhD. | Contact | +31243611111 | Jetty.Weijers@radboudumc.nl |
| Name | Affiliation | Role |
|---|---|---|
| C.M.L. van Herpen, prof. MD. PhD. | Radboud University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radboudumc | Recruiting | Nijmegen | Gelderland | 6500HB | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39304797 | Background | Weijers JAM, Verhaegh GW, Lassche G, van Engen-van Grunsven ACH, Driessen CML, van Erp NP, Jonker MA, Schalken JA, van Herpen CML. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. BMC Cancer. 2024 Sep 20;24(1):1174. doi: 10.1186/s12885-024-12889-0. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017273 | Goserelin |
| C053541 | bicalutamide |
| D000068538 | Dutasteride |
| ID | Term |
|---|---|
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
Not provided
Not provided
Patients will be included into two cohorts based on their previous treatments, either ADT-naïve (cohort A) or ADT-resistant patients (cohort B). In cohort A, the randomization will result in the allocation of the control arm (goserelin and bicalutamide) and experimental arm (goserelin, bicalutamide, and dutasteride) in a 1:1 ratio. In cohort B, patients ADT-resistant will be enrolled receiving similar therapy to the experimental arm, i.e. goserelin, bicalutamide, and dutasteride.
Cohort A is closed for inclusion as of April 18, 2024.
Not provided
Not provided
Not provided
Not provided
|
| Bicalutamide 50 mg | Drug | Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw. |
|
|
| Dutasteride 0.5 mg | Drug | Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw. |
|
|
| Clinical benefit rate (CBR) | Response will be measured according to RECIST version 1.1, the CBR is defined as the confirmed CR or PR at any time or stable disease (SD) of at least 6 months. Every 12 weeks a CT/MRI scan will be made to asses the clinical benefit rate until PD. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Overall survival (OS) | The OS is defined as the time from study enrolment to the date of death to any cause. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years |
| Quality of Life (QoL) based on the EORTC QLQ-C30 questionnaire | Quality of Life (QoL) based on the EORTC QLQ-C30 questionnaire. Participants are asked to fill in the questionnaires in week 0 (before start of treatment, baseline), every 12 weeks, and at PD. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Quality of Life (QoL) based on the EORTC QLQ-H&N43 questionnaire | Quality of Life (QoL) based on the EORTC QLQ-H&N43 questionnaire. Participants are asked to fill in the questionnaires in week 0 (before start of treatment, baseline), every 12 weeks, and at PD. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Quality of Life (QoL) based on the EORTC QLQ-SHQ22 questionnaire | Quality of Life (QoL) based on the EORTC QLQ-SHQ22 questionnaire. Participants are asked to fill in the questionnaires in week 0 (before start of treatment, baseline), every 12 weeks, and at PD. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Pain level assessed by the VAS (visual analog scale) questionnaire | Scale range 0-10, in which a higher score represents more pain. Participants are asked to fill in the questionnaires in week 0 (before start of treatment, baseline), every 12 weeks, and at PD. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Adverse Events according to CTCAE v5.0 | Adverse events will be recorded using International Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, the investigator will assess whether those events are drug related. Every OPD visit (every 3 months until PD) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years |
| Circulating tumor DNA (ctDNA) levels | ctDNA levels will be assessed to evaluate whether treatment response and disease progression can be predicted. Baseline, 3 months, 6 months, and at PD. | through study completion, estimated after 3 years |
| mRNA expression levels of AR and AR splice variants | mRNA expression of AR and AR splice variants on baseline and post-treatment tumor tissue samples to evaluate whether treatment response and disease progression can be predicted. Pre-treatment and post-treatment (i.e. PD) | through study completion, estimated after 3 years |
| mRNA expression levels of SRD5A1/SRD5A2 | mRNA expression of SRD5A1/SRD5A2 on baseline and post-treatment tumor tissue samples to evaluate whether treatment response and disease progression can be predicted. Pre-treatment and post-treatment (i.e. PD) | through study completion, estimated after 3 years |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
| D001378 | Azasteroids |
| D013260 | Steroids, Heterocyclic |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |